利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.017 秒)

    Treatment for eye disorder
    7.
    发明授权
    Treatment for eye disorder 有权
    治疗眼病

    公开(公告)号：US08298521B2

    公开(公告)日：2012-10-30

    申请号：US12126100

    申请日：2008-05-23

    申请人： Daniel M. Schwartz ,  Scott Fraser ,  Robert H. Grubbs ,  Justin P. Gallivan ,  Changjun Yu

    发明人： Daniel M. Schwartz ,  Scott Fraser ,  Robert H. Grubbs ,  Justin P. Gallivan ,  Changjun Yu

    IPC分类号： A61K31/74

    CPC分类号： A61K49/0056 ,  A61K38/482 ,  A61K41/00 ,  A61K49/0017

    摘要： The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.

    摘要翻译： 本发明涉及改变眼睛中至少一个组织的至少一部分的物理和/或化学性质。 在具体实施方案中，它涉及任何眼睛疾病的治疗，尽管在具体实施方案中个体具有增厚的布鲁赫氏膜。 使用活化能源来实现Bruch膜的受控扩散增强和/或降解，其能够改善脉络膜和视网膜之间的扩散转运。 给个体施用与膜相关的失活的扩散增强分子，然后将其精确地暴露于诸如光或超声的活化能源。

    Lenses capable of post-fabrication power modification
    8.
    发明授权
    Lenses capable of post-fabrication power modification 有权
    能够进行后制造功率修改的镜头

    公开(公告)号：US07798644B2

    公开(公告)日：2010-09-21

    申请号：US11743119

    申请日：2007-05-01

    申请人： Jagdish M. Jethmalani ,  Daniel M. Schwartz ,  Julia A. Kornfield ,  Robert H. Grubbs ,  Christian A. Sandstedt

    发明人： Jagdish M. Jethmalani ,  Daniel M. Schwartz ,  Julia A. Kornfield ,  Robert H. Grubbs ,  Christian A. Sandstedt

    IPC分类号： A61B3/00

    CPC分类号： G02B3/00 ,  A61F2/1627 ,  A61F2/1635 ,  A61L27/18 ,  A61L2430/16 ,  G02B1/043 ,  G02C7/04 ,  G02C2202/14 ,  C08L83/04

    摘要： The present invention relates to lenses that are capable of post-fabrication power modifications. In general, the inventive lenses comprise (i) a first polymer matrix and (ii) a refraction modulating composition that is capable of stimulus-induced polymerization dispersed therein. When at least a portion of the lens is exposed to an appropriate stimulus, the refraction modulating composition forms a second polymer matrix. The amount and location of the second polymer matrix may modify a lens characteristic such as lens power by changing its refractive index and/or by altering its shape. The inventive lenses have a number of applications in the electronics and medical fields as data storage means and as medical lenses, particularly intraocular lenses, respectively.

    摘要翻译： 本发明涉及能够进行后制造功率修改的透镜。 通常，本发明的镜片包括（i）第一聚合物基质和（ii）能够刺激诱导的聚合分散在其中的折射调节组合物。 当透镜的至少一部分暴露于适当的刺激时，折射调节组合物形成第二聚合物基质。 第二聚合物基质的量和位置可以通过改变其折射率和/或通过改变其形状来改变诸如透镜功率的透镜特性。 本发明的镜片在电子和医疗领域中有许多应用，分别作为数据存储装置和医疗镜片，特别是眼内透镜。

    Treatment for dark adaptation
    10.
    发明授权
    Treatment for dark adaptation 失效
    治疗黑暗适应

    公开(公告)号：US07470660B2

    公开(公告)日：2008-12-30

    申请号：US11055309

    申请日：2005-02-10

    申请人： Daniel M. Schwartz ,  Keith G. Duncan ,  Kathy Bailey ,  John P. Kane ,  Brian Y. Ishida

    发明人： Daniel M. Schwartz ,  Keith G. Duncan ,  Kathy Bailey ,  John P. Kane ,  Brian Y. Ishida

    IPC分类号： A61K31/685 ,  A61K31/7088 ,  A61K38/02 ,  A61K38/10 ,  A61K38/17

    CPC分类号： A61K31/685 ,  A61K31/66 ,  A61K38/17 ,  A61K38/1709 ,  A61K2300/00

    摘要： The present invention addresses the treatment of age-related macular degeneration, and treatment of individuals with impaired visual function such as impaired dark adaptation, using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration and improving impaired dark adaptation. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.

    摘要翻译： 本发明涉及使用与动脉粥样硬化相似的致病机制的调节来处理年龄相关性黄斑变性和视力功能受损的个体的治疗，例如暗适应受损。 在进一步的具体实施方案中，增加反向胆固醇转运的组合物被用作年龄相关性黄斑变性和改善受损的黑暗适应的治疗靶标。 在一个具体的实施方案中，通过递送载脂蛋白A1，特别是模拟肽来减少视网膜色素上皮和/或Bruch's膜的脂质含量。